Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Brooklyn, New York Clinical Trials

A listing of Brooklyn, New York clinical trials actively recruiting patient volunteers.

RESULTS

Found (20) clinical trials

Primary end point: To evaluate the safety and tolerability of INCB 054707-202. Secondary end point: To evaluate the systemic exposure and evaluate the efficacy of INCB 054707-202. Overall design: This is a Phase 2, multicenter, open-label, single-arm study to assess the safety of 15 mg QD INCB 054707-202 over 8 ...

Phase

1.54 miles

Learn More »

A Trial of Linaclotide 290 g in Patients With Irritable Bowel Syndrome With Constipation

12 week treatment period followed by 4-week Randomized Withdrawal (RW) Period.

Phase

2.5 miles

Learn More »

A Study Evaluating ABI-H0731+ NUC vs NUC Alone for the Treatment of Viremic HBeAg-positive CHB Patients

This is a Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Patients With Chronic Hepatitis B

Phase

3.53 miles

Learn More »

A Study of JNJ-63723283 a Programmed Cell Death Receptor-1 (PD-1) Inhibitor Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer

This study is of participants with mCRPC who have progressed after therapy with an androgen receptor (AR)-targeted agent and have not received chemotherapy. Participants must have confirmed prostate-specific antigen (PSA) progression per Prostate Cancer Clinical Trials Working Group (PCWG3) criteria. The primary hypothesis is that treatment with JNJ-63723283 and apalutamide ...

Phase

3.53 miles

Learn More »

A Study Evaluating ABI-H0731 as Adjunctive Therapy in HBeAg-positive Patients With Chronic Hepatitis B

This is a Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731 as Adjunctive Therapy in Virally-suppressed HBeAg-positive Patients with Chronic Hepatitis B

Phase

3.53 miles

Learn More »

A Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Combination With Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

This is a randomized (individuals assigned to study treatment by chance), double-blind (individuals and study personnel will not know the identity of study treatments), placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial)-controlled study to compare ...

Phase

3.53 miles

Learn More »

RESOLUTE ONYX Post-Approval Study (Bifurcation Cohort)

To observe the continued performance of the Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System in a real-world more-comer population. To collect data on the safety and efficacy of the Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System in bifurcated lesions.

Phase N/A

3.53 miles

Learn More »

Music to Reduce Use of Smoking in Patients With Schizophrenia

The purpose of this study is to explore the impact of self-selected music listening which targets disrupting the reward process maintaining smoking and additionally attenuating the reward processing deficits associated with schizophrenia. Five participants with schizophrenia/schizoaffective disorder who smoke/nicotine will participate in an individual session of self-selected music listening for ...

Phase N/A

3.53 miles

Learn More »

Study of CDX-3379 a Human Monoclonal Antibody Targeting ERBB3 in Combination With the MEK Inhibitor Trametinib in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma

Primary Objectives: Phase 1b: To determine the RP2D and assess the toxicity and tolerability of the combination of CDX-3379 (ERBB3 antibody) and trametinib (MEK inhibitor) in NRAS and BRAF/NRAS WT melanoma patients Phase 2: To estimate the response rates and duration of response of the combination of CDX-3379 (ERBB3 antibody) ...

Phase

3.53 miles

Learn More »

Emergency Department Connection to Care With Buprenorphine for Opioid Use Disorder

The purpose of this study is to learn what resources are needed to improve outcomes for patients with opioid use disorder. The study will look at how patients engage in treatment and the decisions that patients and providers make regarding treatment, specifically buprenorphine treatment, for opioid use disorder. The aims ...

Phase N/A

3.53 miles

Learn More »